Latest News for: gip

Edit

CT-388 Enters Phase III in 2025: Dual GLP-1/GIP Candidate Targets USD 150 Billion Obesity Market ...

GetNews 24 Feb 2026
CT-388 is a once-weekly subcutaneous injectable dual GLP-1/GIP receptor agonist designed for the treatment of obesity and type 2 diabetes mellitus (T2D) ... Dual GLP-1/GIP Agonism + Biased Signaling.
Edit

Canadian Investment Regulatory Organization Trading Halt - GIP Français

Canada Newswire 18 Feb 2026
VANCOUVER, BC, Feb. 18, 2026 /CNW/ - The following issues have been halted by CIRO. Company. Green Impact Partners Inc. TSX-Venture Symbol. GIP. All Issues. Yes. Reason. Pending News. Halt Time (ET). 7.45 AM ... .
Edit

American GIP and Swedish EQT plan to acquire AES worth $10.5 billion

AK&M Information Agency 05 Feb 2026
American GIP and Swedish EQT plan to acquire AES worth $10.5 billion . AKM.RU ....
Edit

LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies

Pharmiweb 30 Jan 2026
The study compares a topical, skin-applied CPP formulation of semaglutide, a GLP-1 analogue representative of GLP/GIP-based therapies, against injectable semaglutide and untreated controls in a glucose tolerance model.
Edit

Chevron Adds GIP's Thomas Horton to Board

Rigzone 28 Jan 2026
Chevron appointed Thomas Horton, a partner at Global Infrastructure Partners of global asset manager BlackRock, as an independent director, expanding its board to 13 members ... .
Edit

Genentech Announces Positive Phase II Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People ...

The Joplin Globe 27 Jan 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jan 27, 2026-- ... .
Edit

GIP shortlists 4 companies for Vena Energy India sale

The Times of India 27 Jan 2026
This sale is part of GIP's portfolio reshaping in India. .
Edit

GIPS hosts 'Board 101' public workshops

The Grand Island Independent 27 Jan 2026
The Grand Island Public Schools will offer "GIPS Board 101" workshops throughout January and February ... .
Edit

Genentech Announces Positive Phase II Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People Living With Obesity (Genentech Inc)

Public Technologies 27 Jan 2026
). The text version of this document is not available ... Disclaimer. Genentech Inc.
Edit

LIR Life Sciences Launches Comparative Animal Study to Advance Transdermal Delivery of Second Generation GLP/GIP-based ...

ACCESSWIRE 16 Jan 2026
Working with its scientific collaborators, LIR will assess whether a CPP-enabled, skin-applied formulation of a representative second generation GLP/GIP-based obesity therapy can achieve meaningful biological activity when delivered through the skin.
Edit

Dole-Davao logs nearly 19% increase in GIP beneficiaries

Sun Star 15 Jan 2026
"At a young age, being part of the GIP helped me become more independent and confident ... Dole-Davao has expanded the role of GIP interns through GIP Care, a youth-driven initiative that promotes social responsibility and community engagement.
Edit

Kailera Therapeutics Announces First Participants Randomized in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP ...

Nasdaq Globe Newswire 12 Jan 2026
Kailera announced the first participants randomized in the global Phase 3 clinical program of GLP-1/GIP receptor dual agonist ribupatide (KAI-9531) ... .
Edit

Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity

PR Newswire 12 Jan 2026
The paper, titled, "Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management ... About GLP-1 and Dual GLP-1/GIP Agonists ... Tirzepatide is a dual GLP-1/GIP receptor agonist that has been approved by the U.S.
Edit

Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity (Viking Therapeutics Inc)

Public Technologies 12 Jan 2026
Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity ... (GIP) receptors ... About GLP-1and Dual GLP-1/GIP Agonists.
Edit

LIR Life Engages Neuland Labs to Advance Development of Cell Penetrating Peptides for Transdermal GLP-1/GIP Platform

ACCESSWIRE 09 Jan 2026
... and manufacturing organization (CDMO), under which Neuland Labs is to provider R&D services to test and advance novel peptide formulations that underpin LIR's transdermal GLP-1/GIP platform.

Article Search

tools
×
×
×
×